title: ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION IN THE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ERA.
abstract: OBJECTIVE
  Anti-vascular endothelial growth factor therapy has improved the prognosis for patients with central retinal vein occlusion (CRVO). However, most studies published to date exclude ischemic CRVO. The purpose of this study was to describe the outcome in eyes with ischemic CRVO treated with anti-vascular endothelial growth factor therapy.
  
  
  METHODS
  Thirty-seven patients with ischemic CRVO from 3 centers were followed for at least 6 months. Data on patient demographic, vision status, and anti-vascular endothelial growth factor treatments were collected.
  
  
  RESULTS
  Average number of injections during the study period was 5. Younger age was associated with improved vision (P = 0.006). Patients with improved visual outcomes tended to have macular edema as the primary indication for treatment, whereas patients with worse outcomes tended to have neovascularization as the primary indication for treatment.
  
  
  CONCLUSIONS
  This study highlights significant variability in the use of anti-vascular endothelial growth factor therapy for ischemic CRVO and underscores that eyes with neovascularization tend to have worse visual outcomes.
authors.affiliation: David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
authors.forename: Emily K
authors.initials: EK
authors.lastname: Tam
authors.affiliation: Benjamin Eye Institute, Los Angeles, California.
authors.forename: Pamela
authors.initials: P
authors.lastname: Golchet
authors.affiliation: David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
authors.forename: Madeline
authors.initials: M
authors.lastname: Yung
authors.affiliation: Southeastern Retina Associates, Chattanooga, Tennessee.
authors.forename: Francis C
authors.initials: FC
authors.lastname: DeCroos
authors.affiliation: The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania.
authors.forename: Marc
authors.initials: M
authors.lastname: Spirn
authors.affiliation: Department of Ophthalmology, Medical Retina Unit, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland.
authors.forename: Lydia
authors.initials: L
authors.lastname: Lehmann-Clarke
authors.affiliation: Department of Ophthalmology, Medical Retina Unit, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland.
authors.forename: Aude
authors.initials: A
authors.lastname: Ambresin
authors.affiliation: Stein Eye Institute, University of California, Los Angeles, Los Angeles, California. Doheny Eye Institute, University of California, Los Angeles, Los Angeles, California.
authors.forename: Irena
authors.initials: I
authors.lastname: Tsui
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D058449:Intravitreal Injections; D007511:Ischemia / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology; D008297:Male; D000069579:Ranibizumab / Q000008:administration & dosage*; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014481:United States / Q000453:epidemiology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab